New market study, "Germany Pharmaceuticals & Healthcare Report Q2 2015", has been published

One of the largest markets in Europe, Germany will continue to experience rising demand for pharmaceuticals, sustained by an ageing population with a strong bias towards patented medicines. In spite of this, additional restrictions on reimbursement, tempered by government's desire to preserve an industry integral to Germany's positive balance of trade and international prestige, will nonetheless constrain revenues and intensify already fierce competition amongst drugmakers. As such, drugmakers will perceive a positive, but deteriorating German operating environment, marked by intensifying price competition, increasingly burdensome regulation and an economic environment particularly susceptible to sudden external shocks.

Headline Expenditure Projections

* Pharmaceuticals: from EUR39.95bn (USD53.53bn) in 2014 to EU39.83bn (USD49.79bn) in 2015; -0.3% in local currency terms and -7.0% in US dollar terms. Downwards from Q115
* Healthcare: from EUR310.11bn (USD415.54) in 2014 to EUR317.41bn (USD396.76bn) in 2015; +2.4% in local currency terms and -4.5% in US dollar terms . Upwards in local currency from Q115

Full Report Details at
- http://www.fastmr.com/prod/956857_germany_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

Risk/Reward Index: In BMI's Q215 Western European Risk/Reward Index (RRI), Germany continues to lose ground to other regional markets with a score of 72.4 out of 100, down from 72.9 in Q115. Weighed down by a reduced country rewards score, Germany is ranked as the 3 ^rd most attractive market for drugmakers out of 15 in the region, relinquishing 2 ^nd place to Switzerland. Germany remains one of the largest and most attractive pharmaceutical markets in the Western European region, with strong industry rewards and a markedly above average risks score, illustrative of the country's favourable operating environment. However, potential rewards are capped by increasingly burdensome reimbursement and pricing regulation and a shrinking base of contributors to the public and private funding of healthcare.

Key Trends and Developments

* In December 2014,...

The Germany Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Germany Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Germany pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Germany, to test other views - a key input for successful budgeting and strategic business planning in the German pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015